ClinicaliQ Trial Snapshot
- NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer — Active Not Recruiting • Phase I • Oncology • NCT06459869.
- NG-350A combined with standard chemoradiotherapy improves outcomes in high-risk locally advanced rectal cancer patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence. Conditions: Locally Advanced Rectal Cancer (LARC) Interventions: NG-350A IV administration, Capecitabine oral administration, Radiotherapy Lead Sponsor: Akamis Bio Planned Enrollment: 30 participants